Why Has Pfizer Inventory Traditionally Carried out So Poorly for Many years [Explained]

I’ve been poking round Pfizer’s inventory currently, at the moment sitting at a measly $26.42 as of February 27, 2025. Man, it’s a tragic sight. I imply, this can be a firm that’s been round ceaselessly, however when you’ve held onto their inventory because the late ‘90s, you’re mainly proper again the place you began. No beneficial properties, nada. In the meantime, their rivals like Eli Lilly and Novo Nordisk are out right here crushing it. What offers? I wished to determine why Pfizer’s been such a letdown for many years, so I rolled up my sleeves and dug in. Right here’s what I discovered.

The Good Ol’ Days (That Didn’t Final)

Let’s rewind a bit.

Again within the late ‘90s and early 2000s, Pfizer was the title in pharma. They’d Lipitor, this ldl cholesterol drug that was printing cash. The corporate used to make over $13 billion a 12 months at its peak. Then it was Viagra, which, effectively, you understand what that did.

Their inventory was flying excessive, hitting one thing like $50 or $60 a share when you modify for inflation. I wasn’t investing again then, however when you have been, you most likely felt like a genius.

Then it began unraveling. Lipitor’s patent ran out in 2011. Generics swooped in, and poof, billions in income gone.

That’s once I began noticing Pfizer’s chart wanting extra like a flatline than a rocket.

Examine that to Eli Lilly, up 585% in 5 years because of medication like Mounjaro, or Novo Nordisk, up 193% with Ozempic. Even Johnson & Johnson, which has had its personal drama, is up 13.5%. Pfizer? Down 19.8%. Ouch.

The Patent Cliff Hit Onerous

So, yeah, shedding Lipitor was a intestine punch.

I get it, pharma lives and dies by patents. However Pfizer didn’t appear prepared for all times after that blockbuster.

They’ve received stuff like Eliquis, a blood thinner, and Prevnar, a vaccine, that are doing alright, however nothing’s stuffed that Lipitor-sized gap.

In the meantime, Lilly and Novo are driving this weight problems and diabetes wave with their GLP-1 medication. Over right here, I’m questioning why Pfizer didn’t soar on that practice.

Their pipeline’s received 112 candidates, which sounds spectacular, however it appears like they’re swinging and lacking on the massive traits.

COVID: A Flash within the Pan

Okay, let’s discuss concerning the COVID years, as a result of that’s once I thought Pfizer may flip it round.

They teamed up with BioNTech, dropped the primary massive vaccine, and adopted it with Paxlovid.

In 2022, they raked in $100 billion, nuts, proper? The inventory hit $61.71 in late 2021, and I used to be like, “Perhaps they’re again.” Nope. As soon as the pandemic cooled off, demand tanked, and income dropped to $58.5 billion by 2023.

Their market cap’s now $149 billion, whereas Lilly’s at $734 billion and Novo’s at $576 billion.

That COVID bump was like a sugar excessive, enjoyable whereas it lasted, however no endurance.

Administration’s Huge Bets (That Aren’t Paying Off But)

I can’t assist however level a finger on the of us working the present.

Albert Bourla’s been CEO since 2019, and the inventory’s down 30% underneath him whereas the S&P 500’s up 80%. Tough look.

He’s been splashing money on offers, like $43 billion for Seagen in 2023. However I’m not seeing the payoff but. Some activist investor group, Starboard, even referred to as them out for overpaying.

Wanting again, Pfizer’s beloved these massive mergers. Warner-Lambert in 2000, Wyeth in 2009, however they’ve left the corporate bloated and distracted.

Examine that to AbbVie, which spun off, milked Humira, and constructed new winners like Skyrizi. Pfizer’s enjoying checkers whereas others are on chess.

Lacking the Sizzling Tendencies

Right here’s the place I get annoyed.

The market’s obsessive about weight problems and diabetes medication proper now. Lilly and Novo are killing it there. However Pfizer’s late to the celebration. They’ve received this oral GLP-1 factor, danuglipron, within the works, however it’s years behind.

Oncology’s their new focus with Seagen, which is cool, however it’s a crowded subject. Traders don’t appear to belief Pfizer to tug off a win, and actually, with their monitor file, I kinda get it.

You may marvel if shady stuff’s responsible, like that $2.3 billion high-quality in 2009 for sketchy advertising and marketing.

Yeah, that sucked, however it’s not why the inventory’s tanked for many years. Pharma’s filled with authorized messes ( you, J&J talc lawsuits).

I believe, Pfizer’s downside isn’t fraud, it’s technique.

How Do They Repair This?

If I have been Pfizer, I’d be scrambling.

Perhaps purchase a scorching biotech in weight problems, like Viking Therapeutics, to catch up. Or lean exhausting into Eliquis and Seagen’s most cancers medication and make them shine.

Minimize some fats, focus R&D on stuff that’ll really transfer the needle, and inform traders what the plan is. Proper now, it appears like they’re throwing darts blindfolded.

Pfizer’s been a slog as a result of they misplaced their mojo after Lipitor. They wager massive on COVID then crashed.

It’s unusual how effectively Pfizer maintain lacking the traits their rivals are driving. It’s not one factor, it’s a bunch of little stumbles including as much as an enormous faceplant.

I nonetheless suppose they might flip it round with the precise strikes. However man, they’ve received work to do.

What do you reckon? Suppose Pfizer’s received a shot, or are they caught within the mud ceaselessly? Hit me up, I’m curious what you suppose.

Have a cheerful investing.